Time to deterioration of symptoms with durvalumab in stage III, locally advanced, unresectable NSCLC: Post-hoc analysis of PACIFIC patient-reported outcomes


Hui R., Ozguroglu M., Villegas A., Daniel D., Vicente D., Murakami S., ...More

JOURNAL OF THORACIC ONCOLOGY, vol.13, no.4, 2018 (SCI-Expanded, Scopus)